TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12599047

Group type: EXPERIMENTAL
Intervention: Breast-milk HIV-1 RNA levels
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Colostrum/early milk
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Breast-milk viral RNA levels
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Breast-milk virus load
Number of subjects: 275
Study: 11321644

Group type: EXPERIMENTAL
Intervention: Electromagnetic field of a GSM-standard mobile phone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo experiment
Number of subjects: 8
Study: 9387950

Group type: EXPERIMENTAL
Intervention: Weekly infusion of human alpha1-antitrypsin (alpha1-AT) at a dosage of 60 mg x kg(‐1) body weight
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 295
Study: 8187805

Group type: EXPERIMENTAL
Intervention: Intra‐operative peritoneal serum application
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 30
Study: 3299566

Group type: EXPERIMENTAL
Intervention: Ambroxol 120 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ambroxol 30 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30566847

Group type: EXPERIMENTAL
Intervention: Prednisone/Azathioprine/N‐Acetylcysteine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Immunosuppression (placebo arm of ACE‐IPF)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Immunosuppression (propensity-matched University of Texas Southwestern Medical Center IPF cohort)
Number of subjects: 118
Study: 27647855

Group type: EXPERIMENTAL
Intervention: TGF‐β1 mAb (2-, 10-, or 50-mg monthly subcutaneous dosing for 12 months)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 25695180

Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24494285

Group type: EXPERIMENTAL
Intervention: Acupuncture plus fire needling (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Acupuncture only (Group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Follow-up for cured cases in Group A
Number of subjects: 180
Study: 20953803

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day 2 (P2)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day 4 (P4)
Number of subjects: 351
Study: 19723128

Group type: EXPERIMENTAL
Intervention: 1% voriconazole eye drops, hourly for four doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1% voriconazole eye drops, four times a day for 3 days
Number of subjects: 10
Study: 17545265

Group type: EXPERIMENTAL
Intervention: Compomer restorations
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Composite restorations
Number of subjects: 534

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 534
Study: 15302194

Group type: EXPERIMENTAL
Intervention: Immediate delivery (n=296)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Delayed delivery (n=292)
Number of subjects: 588
Study: 11476384

Group type: EXPERIMENTAL
Intervention: Elite skiers (n=120)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control subjects (n=39)
Number of subjects: 120
Study: 9823827

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (4:1 ratio), initiated and maintained after hospitalization
Number of subjects: 51
Study: 7865192

Group type: EXPERIMENTAL
Intervention: Community placements after discharge
Number of subjects: 114
Study: 2818656

Group type: EXPERIMENTAL
Intervention: Aerobic walking
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aerobic aquatics
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonaerobic range of motion (controls)
Number of subjects: 120
Study: 1163927

Group type: EXPERIMENTAL
Intervention: New topical ophthalmic delivery systems (specific systems not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pilocarpine drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New topical ophthalmic delivery systems
Number of subjects: 0
Study: 31668861

Group type: EXPERIMENTAL
Intervention: Neutral-pressure needleless connectors (NP-NCs)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Positive-pressure needleless connectors (PP-NCs)
Number of subjects: 70
Study: 30659987

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 504

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 504
Study: 28971620

Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study: 26237623

Group type: EXPERIMENTAL
Intervention: PPIA preparation
Number of subjects: 93

Group type: COMPARATOR
Intervention: PPIA standard
Number of subjects: 93
Study: 22646659

Group type: EXPERIMENTAL
Intervention: Daily text message intervention (N = 8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Weekly general health messages (N = 10)
Number of subjects: 18
Study: 21069290

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (low, medium, and high doses)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20019427

Group type: EXPERIMENTAL
Intervention: Experimental bonding agents containing calcium phosphates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clearfil SE Bond/Bond (Control)
Number of subjects: 0
Study: 16455838

Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 36 microg (delivered)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Salbutamol pressurised metered-dose inhaler 1,600 microg (metered)
Number of subjects: 78
Study: 15266726

Group type: EXPERIMENTAL
Intervention: Self-protective behaviors
Number of subjects: 1355
Study: 11299267

Group type: EXPERIMENTAL
Intervention: Standardized cycle ergometer training
Number of subjects: 633
Study: 9767205

Group type: EXPERIMENTAL
Intervention: Buprenorphine (mean daily dose of 8.1 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Methadone (mean daily dose of 39.7 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Slow-release morphine (mean daily dose of 400 mg)
Number of subjects: 9
Study: 8842656

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine hydrochloride 0.3 mg kg‐1 (n = 21)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories 12.5 mg to a dose of 1‐2 mg kg‐1 (n = 19)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No analgesia (Control group, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac group
Number of subjects: 60
Study: 2250501

Group type: EXPERIMENTAL
Intervention: Health education intervention engaging families or significant others in aftercare process
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Health education intervention training patients to become effective health care consumers
Number of subjects: 418
Study: 7208540

Group type: EXPERIMENTAL
Intervention: 0.25 mg clonidine sustained-release capsule, single oral dose, administered for 3 consecutive days
Number of subjects: 8
Study: 31537833

Group type: EXPERIMENTAL
Intervention: Genetically predicted lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted leukemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled genetic predictors of all cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking-related cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted non-smoking related cancers
Number of subjects: 0
Study: 27791345

Group type: EXPERIMENTAL
Intervention: 4-week PNF training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Low back pain educational booklet)
Number of subjects: 42
Study: 26416177

Group type: EXPERIMENTAL
Intervention: Baby Friendly Community Initiative (BFCI) involving regular counseling and support by trained community health workers and health professionals on maternal, infant and young child nutrition.
Number of subjects: 812

Group type: COMPARATOR
Intervention: Control group receiving standard care without the BFCI intervention.
Number of subjects: 812
Study: 24656693

Group type: EXPERIMENTAL
Intervention: MeiboPatch(®) daily for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: LipiFlow(®) single treatment
Number of subjects: 30
Study: 22506791

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Video controls
Number of subjects: 107
Study: 21510568

Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 18824662

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D3 (1000 mg of elemental calcium plus 400 IU of vitamin D3 daily)
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study: 16080281

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg tablets
Number of subjects: 0
Study: 12457629

Group type: EXPERIMENTAL
Intervention: 500 mg daily azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg daily azithromycin
Number of subjects: 0
Study: 10370876

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with red wine supplementation (240 ml/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High fat diet with red wine supplementation
Number of subjects: 42
Study: 8628543

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% administered once daily
Number of subjects: 294

Group type: COMPARATOR
Intervention: Timolol 0.5% administered twice daily
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 294

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 294
Study: 1466214

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.24 mg plus morphine 8 mg (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg plus pethidine 50 mg (Group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intramuscular placebo (Group 3)
Number of subjects: 45
Study: 6700284

Group type: EXPERIMENTAL
Intervention: Short-term group therapy (15 weekly sessions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting list (no immediate treatment)
Number of subjects: 36
Study: 31752977

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 48 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 29573807

Group type: EXPERIMENTAL
Intervention: YIT10347-fermented milk
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo fermented milk
Number of subjects: 100
Study: 26416930

Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 115

Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 115
Study: 23609166

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 24
Study: 21306419

Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine administered i.v.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19140918

Group type: EXPERIMENTAL
Intervention: Device-stored AF episodes
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patient-reported AF-related symptoms
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sensitivity and positive predictive value of symptoms to detect AF
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Comparison of symptomatic and asymptomatic episodes
Number of subjects: 102
Study: 17200266

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (3 oral doses at approximately 1.1 x 10(7) infectious U per dose)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study: 15070921

Group type: EXPERIMENTAL
Intervention: Oral estradiol (1 mg daily) with cyclic micronized progesterone (200 mg for 10 days/month)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral estradiol with cyclic micronized progesterone
Number of subjects: 31
Study: 11286153

Group type: EXPERIMENTAL
Intervention: Statins (lipid-modifying therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8402457

Group type: EXPERIMENTAL
Intervention: High-dose rate (HDR) therapy
Number of subjects: 430

Group type: COMPARATOR
Intervention: Low-dose rate (LDR) therapy
Number of subjects: 430
Study: 3485203

Group type: EXPERIMENTAL
Intervention: PSK (3.0 g/day) plus chemotherapy (CAPF)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Chemotherapy (CAPF) alone
Number of subjects: 7
Study: 30488404

Group type: EXPERIMENTAL
Intervention: Airtraq DLTM
Number of subjects: 60

Group type: COMPARATOR
Intervention: AWS‐200TM
Number of subjects: 60
Study: 27852295

Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK 2.0) prevention program, comprising eight meetings of 60 min each.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Psycho-educational information (control condition).
Number of subjects: 160
Study: 24440672

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg once daily)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mesalamine (3 g once daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 24378101

Group type: EXPERIMENTAL
Intervention: XELOX regimen (oral Xeloda 1000 mg/m² twice a day on days 1-14 and intravenous oxaliplatin 130 mg/m² on day 1, repeated every 21 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Surgery alone (radical resection of gastric cancer)
Number of subjects: 85
Study: 20881334

Group type: EXPERIMENTAL
Intervention: Ultrasound and Color Doppler imaging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 15
Study: 18375270

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine at 2 mL/hr
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine at 5 mL/hr
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline at 5 mL/hr (placebo)
Number of subjects: 60
Study: 16762040

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA)
Number of subjects: 0
Study: 12689735

Group type: EXPERIMENTAL
Intervention: Joint distribution of nonterminal event time estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tests for independence and goodness-of-fit of the model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marginal distribution of the nonterminal event
Number of subjects: 0
Study: 10921699

Group type: EXPERIMENTAL
Intervention: GIK (500 mL D5W + 80 U regular insulin + 40 mEq KCl at 30 mL/hour)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-GIK (D5W at 30 mL/hour)
Number of subjects: 40
Study: 8923553

Group type: EXPERIMENTAL
Intervention: Large display viewed at 1 m
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small display viewed at 33.3 cm (equal retinal size to large display at 1 m)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small display viewed at 1 m
Number of subjects: 0
Study: 1600045

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3518290

Group type: EXPERIMENTAL
Intervention: Ambroxol 1,000 mg in 500 ml 5% glucose infusion i.v. daily from day 1 to day 5 and 2 ml placebo‐injection i.m. on day 1 and day 2
Number of subjects: 34

Group type: COMPARATOR
Intervention: Betamethasone 8 mg i.m. on day 1 and day 2 and 500 ml 5% glucose infusion with a placebo daily from day 1 to day 5
Number of subjects: 34
Study: 28043722

Group type: EXPERIMENTAL
Intervention: Robotic‐assisted total laparoscopic hysterectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 20
Study: 27792174

Group type: EXPERIMENTAL
Intervention: Vegetarian diet (V)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional diet (C)
Number of subjects: 74
Study: 23696633

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) plus naproxen (NPX) 1000 mg daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (PBO) plus naproxen (NPX) 1000 mg daily
Number of subjects: 156
Study: 22079769

Group type: EXPERIMENTAL
Intervention: Glenoid component with inferior tilt (10°)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group with no inferior tilt
Number of subjects: 52
Study: 21714711

Group type: EXPERIMENTAL
Intervention: Atorvastatin titrated from 10-80 mg/day aiming at LDL-C target of <100 mg/dl (group A)
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Atorvastatin titrated from 10-80 mg/day aiming at LDL-C target of <130 mg/dl (group B)
Number of subjects: 1123
Study: 19352377

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 microg/day)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 microg/day)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 16749569

Group type: EXPERIMENTAL
Intervention: Group A: Anesthesia induced with fentanyl 2 microg/kg and propofol 2-3 mg/kg, maintained with isoflurane 0.8-1.2% and fentanyl infusion 1-2 mcg/kg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group B: Anesthesia induced with sufentanyl 0.2 mcg/kg and propofol 2-3 mg/kg, maintained with propofol infusion 6-12 mg/kg/h and sufentanyl infusion 0.2-0.4 mcg/kg/h
Number of subjects: 20
Study: 15277618

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg QD
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg BID
Number of subjects: 546

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 546
Study: 10945314

Group type: EXPERIMENTAL
Intervention: Methoxsalen 10 mg plus nicotine 4 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Methoxsalen 30 mg plus nicotine 4 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo plus nicotine 4 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 28
Study: 9455085

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 77
Study: 8404790

Group type: EXPERIMENTAL
Intervention: Wheat Bran (WB)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sugarbeet Fiber (SBF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Self-Selected Diet (SS)
Number of subjects: 17
Study: 3811806

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 28

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 28
Study: 29443653

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No Chemotherapy (no CT)
Number of subjects: 162
Study: 27099924

Group type: EXPERIMENTAL
Intervention: High in industrial TFA (iTFA; 3.7% energy)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High in TFA from ruminants (rTFA; 3.7% energy)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low in TFA (control; 0.8% energy)
Number of subjects: 9
Study: 24887252

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25% at 1 ml/kg and neostigmine 1.5 ug/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Caudal bupivacaine 0.25% at 1 ml/kg
Number of subjects: 66
Study: 21655934

Group type: EXPERIMENTAL
Intervention: Computer-based patient education
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Conventional education with standard leaflets
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 311
Study: 20378840

Group type: EXPERIMENTAL
Intervention: 28 g/day textured soy flour (containing 14 g of soy protein) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual diet without any soy
Number of subjects: 40
Study: 17826960

Group type: EXPERIMENTAL
Intervention: Cocaine/adrenaline application to the nasal floor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no cocaine/adrenaline application)
Number of subjects: 30
Study: 15703206

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (375 mg/day, titrated up to 2250 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 59
Study: 12437457

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 36
Study: 10352370

Group type: EXPERIMENTAL
Intervention: Whirl bath with valerian (n = 12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whirl bath with pine oil (n = 7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whirl bath with plain water (n = 11)
Number of subjects: 30
Study: 8942593

Group type: EXPERIMENTAL
Intervention: Wound infiltration with tenoxicam 7.5 mg in 40 mL of 0.9% saline (WI group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular tenoxicam 7.5 mg (IM group)
Number of subjects: 50
Study: 1822480

Group type: EXPERIMENTAL
Intervention: Nursing intervention program including four 1 1/2 hour classes held at weekly intervals, selected maternal‐fetal interactive activities, recording of fetal movements, and maintaining of maternal diaries
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nursing intervention program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study: 7035049

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Benzathine/procaine penicillin G
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Cefadroxil monohydrate
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 198
Study: 30741494

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg bid
Number of subjects: 8399

Group type: COMPARATOR
Intervention: enalapril 10 mg bid
Number of subjects: 8399
Study: 28851237

Group type: EXPERIMENTAL
Intervention: Active and Healthy Families (AHF) intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 26025796

Group type: EXPERIMENTAL
Intervention: 1 g intravenous propacetamol
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 2 g intravenous propacetamol
Number of subjects: 111